During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss the implications of measurable residual disease (MRD) on clinical practice and trial design in multiple myeloma (MM). The meeting opened with a presentation by Bruno Paiva and featured a discussion including Paul Richardson, Hang Quach, Sonja Zweegman, and Rakesh Popat.  

During their presentation, Bruno Paiva explored the evolving role of MRD in MM, highlighting both clinical and research applications. Paiva reviewed current MRD detection methods, evaluated sustained MRD negativity as an indicator for long-term survival outcomes, discussed the value of MRD as an early endpoint in clinical trials, and outlined scenarios where MRD could guide treatment decisions, such as fixed-duration therapy or reinitiation upon MRD resurgence. 

Hosted on Acast. See acast.com/privacy for more information.